Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease
Álvaro Petersen-Uribe, Marcel Kremser, Anne‐Katrin Rohlfing, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 11179-11179
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?
Elena Domingo, Patrice Marqués, Vera Francisco, et al.
Pharmacological Research (2024) Vol. 200, pp. 107058-107058
Open Access | Times Cited: 11
Platelets as an inter‐player between hyperlipidaemia and atherosclerosis
Nailin Li
Journal of Internal Medicine (2024) Vol. 296, Iss. 1, pp. 39-52
Open Access | Times Cited: 11
PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction
Meidi Utami Puteri, Nuriza Ulul Azmi, Mitsuyasu Kato, et al.
Life (2022) Vol. 12, Iss. 2, pp. 190-190
Open Access | Times Cited: 29
Lipid-Lowering Therapy after Acute Coronary Syndrome
Edita Pogran, Achim Leo Burger, David Zweiker, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 2043-2043
Open Access | Times Cited: 6
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
Vittoria Cammisotto, Francesco Baratta, Paola Simeone, et al.
Antioxidants (2022) Vol. 11, Iss. 3, pp. 569-569
Open Access | Times Cited: 24
PCSK9 as an Atherothrombotic Risk Factor
Tadeja Sotler, Miran Šebeštjen
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 1966-1966
Open Access | Times Cited: 16
Large-scale lipidomics profiling reveals characteristic lipid signatures associated with an increased cardiovascular risk
Tobias Harm, Kristina Dittrich, Adrian Brun, et al.
Clinical Research in Cardiology (2023) Vol. 112, Iss. 11, pp. 1664-1678
Open Access | Times Cited: 15
Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9
Nicola Ferri, Massimiliano Ruscica, Maria Giovanna Lupo, et al.
Pharmacological Research (2022) Vol. 184, pp. 106439-106439
Open Access | Times Cited: 21
Exploitation of platelets for antitumor drug delivery and modulation of the tumor immune microenvironment
Jie Guo, Mengfei Wang, Yong‐Guan Zhu, et al.
Acta Materia Medica (2023) Vol. 2, Iss. 2
Open Access | Times Cited: 12
Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition
Efthymios Ziogos, Stephen P. Chelko, Tarek Harb, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2023) Vol. 9, Iss. 7, pp. 636-646
Closed Access | Times Cited: 12
Evolocumab attenuates myocardial ischemia/reperfusion injury by blocking PCSK9/LIAS-mediated cuproptosis of cardiomyocytes
Zeqian Li, Lei Guo, Yuqiu An, et al.
Basic Research in Cardiology (2025)
Closed Access
Regulation of Platelet Function by HDL
M. Pilard, Sara Babran, C. Martel
Arteriosclerosis Thrombosis and Vascular Biology (2025)
Closed Access
Platelet Redox Imbalance in Hypercholesterolemia: A Big Problem for a Small Cell
Alessandro Morotti, Cristina Barale, Elena Melchionda, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11446-11446
Open Access | Times Cited: 15
PCSK9 inhibitor attenuates atherosclerosis by regulating SNHG16/EZH2/TRAF5‐mediated VSMC proliferation, migration, and foam cell formation
Yan Liu, Yueyan Zhao, Panyang Feng, et al.
Cell Biology International (2023) Vol. 47, Iss. 7, pp. 1267-1280
Closed Access | Times Cited: 9
Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review)
Shan Chong, Guangyan Mu, Xinan Cen, et al.
International Journal of Molecular Medicine (2024) Vol. 53, Iss. 6
Open Access | Times Cited: 3
Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
Marianna Puccini, Ulf Landmesser, Ursula Rauch
Metabolites (2022) Vol. 12, Iss. 3, pp. 226-226
Open Access | Times Cited: 14
Genetic analysis of the PCSK9 locus in psychological, psychiatric, metabolic and cardiovascular traits in UK Biobank
Rachel Hay, Breda Cullen, Nicholas Graham, et al.
European Journal of Human Genetics (2022) Vol. 30, Iss. 12, pp. 1380-1390
Open Access | Times Cited: 14
Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
Sabina Ugovšek, Miran Šebeštjen
Journal of Clinical Medicine (2022) Vol. 11, Iss. 13, pp. 3625-3625
Open Access | Times Cited: 13
Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis
Bayan Moustafa, Daniel Oparowski, Sofia Testai, et al.
Journal of Stroke and Cerebrovascular Diseases (2024) Vol. 33, Iss. 4, pp. 107633-107633
Closed Access | Times Cited: 2
Machine learning insights into thrombo-ischemic risks and bleeding events through platelet lysophospholipids and acylcarnitine species
Tobias Harm, Xiaoqing Fu, Moritz Frey, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Drug–Drug Interaction between Antiplatelet Therapy and Lipid-Lowering Agents (Statins and PCSK9 Inhibitors)
Karsten Schrör, Dietmar Trenk, Freek W.A. Verheugt
Thrombosis and Haemostasis (2022) Vol. 123, Iss. 02, pp. 166-176
Closed Access | Times Cited: 10
Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
Shuai Wang, Di Fu, Huixing Liu, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 9
Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
Erica Gianazza, Chiara Macchi, Cristina Banfi, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 5
PCSK9 inhibition ameliorates experimental autoimmune myocarditis by reducing Th17 cell differentiation through LDLR/STAT-3/ROR-γt pathway
Miao Yu, Wenjing Tang, Wei Liang, et al.
International Immunopharmacology (2023) Vol. 124, pp. 110962-110962
Closed Access | Times Cited: 5
Machine-learning-based analysis of the sensitivity and specificity on lipid-lowering effect of one-month-administered statins
Huiqin Liu, Ronghong Jiao, Lingling Wang, et al.
Medicine (2023) Vol. 102, Iss. 9, pp. e33139-e33139
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top